PAD is a suspected disease in the field of blood tumors, with complex clinical outcomes and often involving multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological activation.
The platform can assist in matching the needs of a team of authoritative national and international experts to provide accurate diagnosis and treatment programs. Individualised development of treatment programs for PAD, usually including drug therapy, rehabilitation interventions, and regular follow-up to multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of adrenal myeloma. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.